288 - Optimal Site of Care for Administration of Long-Acting Respiratory Syncytial Virus (RSV) Antibodies in the United States (US)

Poster Number: 288
Publication Number: 288.407

Christopher B. Nelson, Sanofi, Swiftwater, PA, United States; Brenna Brady, Merative, Cambridge, MA, United States; Megan Richards, Merative, Ann Arbor, MI, United States; Carolyn R.. Lew, Merative, Ann Arbor, MI, United States; William V. La Via, Sanofi, Pacific Palisades, CA, United States; Michael E. Greenberg, Sanofi, Swiftwater, PA, United States; Christopher Rizzo, Sanofi, Strongsville, OH, United States

Background: New long-acting antibodies for the single dose prevention of respiratory syncytial virus (RSV) lung infection are in development to be administered to all infants before or during their first RSV season. For infants born during the season, administration as soon as feasible after birth is expected to provide optimal protection.

Objective:  This study examined the timing of a first outpatient visit after birth hospitalization for US infants with commercial and Medicaid insurance.

Design/Methods: Outcome: Time to the first outpatient visit following birth-hospitalization discharge (FOV). This study used the Merative^TM MarketScan^® Commercial and Multi-state Medicaid Databases. Timeframe: April 2015 - September 2021. Population: US infants with a birth hospitalization of up to 5 days.

Results: Since April 2020 (COVID era), 87.0% of commercially insured infants had an FOV within 5 days as compared to 77.7% of Medicaid infants (Table 1).  93.5% of commercially insured infants had an FOV within 14 days as compared to 86.6% of Medicaid infants (Table 1). There were no differences between infants born during the RSV season (November-March) and out-of-season (April-October).

Conclusion(s): While the percent of infants with FOV within 5 days increased in the COVID era, Medicaid infants still lag commercially insured infants. Approximately 1 in 7 commercially insured and 1 in 4 Medicaid infants do not have an outpatient visit within 5 days of birth hospitalization discharge. For US infants born during the RSV season, administration of long-acting RSV antibodies prior to birth hospitalization discharge could ensure optimal uptake.